Related Experiment Videos

[Congestive heart failure treated by a combination of cyclovirobuxine D with digoxin]

M Yan1

  • 1Shanghai Jin-An District Central Hospital.

Zhong Xi Yi Jie He Za Zhi = Chinese Journal of Modern Developments in Traditional Medicine
|February 1, 1990
PubMed

Insights

Combination therapy with digoxin and cyclovirobuxine D showed a 45.5% positive effect in congestive heart failure patients. Serum digoxin levels remained stable, supporting long-term, safe use of this combined treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Congestive heart failure (CHF) remains a significant cause of morbidity and mortality.
  • Optimizing pharmacotherapy for CHF is crucial for improving patient outcomes.
  • Combination therapy may offer synergistic benefits in managing complex cardiac conditions.

Purpose of the Study:

  • To evaluate the efficacy and safety of combined digoxin and cyclovirobuxine D in treating congestive heart failure.
  • To assess the impact of this combination therapy on serum digoxin concentrations.
  • To provide pharmacokinetic rationale for the long-term use of digoxin and cyclovirobuxine D.

Main Methods:

  • A cohort of patients with congestive heart failure received combined treatment with digoxin and cyclovirobuxine D.
  • Treatment outcomes were assessed, with a focus on the overall positive effect rate.
  • Serum digoxin concentrations were measured before and after the combined treatment period in a subset of patients.

Main Results:

  • The combination therapy demonstrated a promising positive effect in 45.5% of patients.
  • Serum concentrations of digoxin showed no significant difference before and after the combined treatment (P < 0.05).
  • These findings suggest predictable drug behavior within the combination.

Conclusions:

  • Combined digoxin and cyclovirobuxine D therapy is effective in a notable percentage of congestive heart failure patients.
  • The stability of serum digoxin levels supports the safety profile for extended treatment durations.
  • This study provides a pharmacokinetic basis for the long-term and safe application of this dual-drug regimen.

Related Concept Videos